SLC5A2 and diabetic kidney disease: Regarding DKD patients in the CREDENCE study, reduction of risk for renal composite outcome with canagliflozin was also apparent in subgroups of patients with well-controlled diabetes, suggesting the effect of SGLT2 inhibitors on kidney function is unlikely to be mediated by further improvement of glycemic control62.